Institutional members access full text with Ovid®

Share this article on:

A 3-Year Pilot Study with 1,25-Dihydroxyvitamin D, Calcium, and Calcitonin for Severe Osteodystrophy in Primary Biliary Cirrhosis

Floreani, A. M.D.; Zappala, F. M.D.; Fries, W. M.D.; Naccarato, R. M.D.; Plebani, M. M.D.; D'Angelo, A. M.D.; Chiaramonte, M. M.D.

Journal of Clinical Gastroenterology: June 1997 - Volume 24 - Issue 4 - p 239-244
Original Studies

We carried out a 3-year pilot study of 59 consecutive women with osteoporosis of primary biliary cirrhosis (PBC), allocating them to two groups according to the severity of bone demineralization assessed by means of dual-photon absorptiometry (DPA) of the lumbar spine. Group A (36 patients; bone mineral density [BMD] > 0.800 g/cm2) received no treatment; group B (23 patients; BMD < 0.800 g/cm2) was treated as follows: oral 1,25-dihydroxyvitamin D (0.5 μg twice a day for 5 days) followed by a 1-month course with oral calcium carbonate (1,500 mg/day) + carbocalcitonin (40 UMRC intramuscularly three times weekly). This treatment was repeated every 3 months. The following parameters were assessed at baseline and every 12 months: DPA, serum and urinary minerals, serum parathyroid hormone (PTH), osteocalcin (BGP), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D.

During follow-up, 11 initially untreated patients whose BMD dropped below 0.800 g/cm2 were switched to the treatment group (8 after 12 months and 3 after 24 months). No significant changes were observed in either group for PTH, BGP, or vitamin D metabolites. Comparing patients who were always treated, those who were never treated, and those who switched to the treatment group (ever treated) in this 36-month period, the percentage of annual bone loss in the never-treated patients was significantly less (p < 0.002) than in the ever-treated patients, suggesting the presence of two subgroups in PBC patients; one with rapid bone loss and the other with slow bone loss. Moreover, in the ever-treated patients, ADFR (activate, depress, free, repeat) therapy resulted in an improvement in BMD (p < 0.05 compared with the value before therapy). We conclude that ADFR therapy is effective in the treatment of patients with PBC with severe osteodystrophy, despite no change in osteoblastic activity, although controlled, randomized studies are in order to confirm our data.

From the Department of Gastroenterology, Institute of Internal Medicine, Chemical Biochemistry, Medical Pathology I, Institute of Internal Medicine, University of Padova, Padova, Italy.

Received August 2, 1995. Revision sent August 21, 1995. Accepted December 15, 1996.

This study was partially supported by a grant from Ministero dell' Università e della Ricerca Scientifica (40%).

Address correspondence and reprint requests to Dr. A. Floreani, Divisione Gastroenterologia "R. Farini," Via Giustiniani, 2, 35128 Padova, Italy.

© Lippincott-Raven Publishers